Posts

An Observational, Longitudinal Study of Cognition in Medical Cannabis Patients over the Course of 12 Months of Treatment: Preliminary Results

/by

Cannabis use has increased dramatically across the country; however, few studies have assessed the long-term impact of medical cannabis (MC) use on cognition. Studies examining recreational cannabis users generally report cognitive decrements, particularly in those with adolescent onset. As MC patients differ from recreational consumers in motives for use, product selection, and age of onset, we assessed cognitive and clinical measures in well-characterized MC patients over 1 year. Based on previous findings, we hypothesized MC patients would not show decrements and might instead demonstrate improvements in executive function over time.

Read more

A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction

/by

The prevalence of medical cannabis (MC) use in patients with cancer is growing, but questions about safety, efficacy, and dosing remain. Conducting randomized, controlled trials (RCTs) using state-sponsored MC programs is novel and could provide data needed to guide patients and providers.

Read more

Prolonged Medical Cannabis Treatment is Associated With Quality of Life Improvement and Reduction of Analgesic Medication Consumption in Chronic Pain Patients

/by

Chronic non-cancer pain (CNCP) is one of the most prevalent indications for medical cannabis (MC) treatment globally. In this study, we investigated CNCP parameters in patients during prolonged MC treatment, and assessed the interrelation between CNCP parameters and the chemical composition of MC chemovar used.

Read more

Mini-Review Cannabis in palliative care: current challenges and practical recommendations

/by

Pain and symptom control challenges are common in palliative care, and the search for other therapeutic strategies is ongoing. Unfortunately, patients and their caregivers are receiving little information or support from healthcare providers regarding the increasingly popular cannabinoid-based medicines (CBM). Clinicians, meanwhile, feel understandably perplexed by the discrepancy between the available evidence and the rapid interest in which patients and their families have demonstrated for CBM. There is an urgent need to address the many challenges that are delaying the appropriate integration of CBM into clinical practice, notwithstanding the obvious need for a solid general knowledge of pharmacology, mechanism of action and available clinical evidence supporting its use

Read more

Use of Cannabis for Self-Management of Chronic Pelvic Pain

/by

SCC member Kenzi Riboulet-Zemouli identifies a coherent nomenclature for cannabis products (whether derived from Cannabis sativa L. or not). The paper was published in Drug Science, Policy and Law in December of 2020.

Read more

Short-Term Medical Cannabis Treatment Regimens Produced Beneficial Effects among Palliative Cancer Patients

/by

Authors Joshua Aviram, Gil M. Lewitus, Yelena Vysotski, Anton Uribayev, Shiri Procaccia, Idan Cohen, Anca Leibovici, Mahmud Abo-Amna, Luiza Akria, Dmitry Goncharov, Neomi Mativ, Avia Kauffman, Ayelet Shai, Or Hazan,…

Read more

Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study

/by

Authors: Emily M.Webster, Ghanshyam S.Yadav, Stefan Gysler, Blair McNamara, Jonathan Black, Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, Christopher K. Arkfeld, Vaagn Andikyan, Gulden Menderes, Gloria Huang, Masoud Azodi, Dan-Arin Silasi,…

Read more

The practical knowledge, experience and beliefs of US emergency medicine physicians regarding medical Cannabis: A national survey

/by

Author: Kevin M Takakuwa, Frances S Shofer, Raquel M Schears Published in The American Journal of Emergency Medicine  January 2020 Introduction Medical cannabis is legal in 33 US states [ 1…

Read more

A history of the Society of Cannabis Clinicians and its contributions and impact on the US medical cannabis movement

/by

Dr. Kevin M.Takakuwa details the history of the SCC, which is the first and oldest U.S. medical organization promoting the use of medical cannabis.

Read more

Medical Cannabis in Asthmatic Patients.

/by

Authors: Amir Jarjou’i, Gabriel Izbicki
The Israel Medical Association journal : IMAJ, April 2020
—
BACKGROUND: With the increased use of cannabis in the medicinal and recreational domains, it is becoming more important for physicians to better understand its harmful and beneficial effects. Although medical cannabis comes in several forms, the preferred route of administrati…

Read more

Cannabis education needs assessment among Canadian physicians-in-training.

/by

Canadian researchers found that the average training from physicians in training was 25% less than what they desired and that further training was paramount for them to engage in cannabis for therapeutic purposes (2020).

Read more

Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions.

/by

Authors: Joshua D. Brown
Journal of Clinical Medicine, 28 February 2020
—
Tetrahydrocannabinol (THC) is the primary psychoactive ingredient in cannabis. While the safety of THC and cannabis has been extrapolated from millennia of recreational use, medical marijuana programs have increased exposure among medically complex individuals with comorbid co…

Read more